Clinical Trials & Research

There is no constant in healthcare legislation. In the United States, political opponents continue to argue over the future of former President Barack Obama’s Affordable Care Act: Democrats seek to broaden healthcare’s accessibility, while Republicans aim to minimize taxes and shift subsidies away from health-related issues. This is further complicated by conflicting polling surrounding hot-button healthcare issues. These
0 Comments
In just three months, Sanofi automated over 600 approved materials and accounts following this process Add bookmark Download Your Copy We respect your privacy, by clicking “Download Your Copy” you will receive our e-newsletter, including information on Podcasts, Webinars, event discounts, online learning opportunities and agree to our User Agreement. You have the right to
0 Comments
With every new reporting requirement set out by international authorities, the call to transform regulatory information management (RIM) is growing louder. This is not just ISO IDMP but international variations and other transparency initiatives throughout the global life sciences industry. At the same time, life sciences firms themselves are now realising the strategically important role
0 Comments
Practitioners working with patents and know-how licenses – in-house and in private practices – face a number of challenges. In this article, key concerns are addressed relating to ownership, royalties, visibility and protecting licensed IP. Identifying the know-how How to clearly identify the licensed know-how while not compromising its confidentiality is a top issue. In
0 Comments
As the pharma community continue to research and develop hundreds of potential therapies to combat the Covid-19 pandemic, very few initiatives are yet to cross the finishing line into the commercial market. However, in this week’s round up, Pharma IQ shares promising news of a Covid-19 candidate collaboration between Roche and Regeneron that looks to
0 Comments
With the World Health Organization this week publishing a list of the latest Covid-19 candidate vaccines from around the world, Pharma IQ’s weekly round-up looks at developments from the past seven days including news on how the pharma industry plans to handle vaccine disruption and flu season. New pharma partnership prepares air cargo industry for
0 Comments
As the pharma industry stands firm in its commitment to advance the sector to fight Covid-19, news has emerged from the European Commission who intend to streamline the development of therapies using genetically modified organisms to treat Covid-19. The governing body claims this proposal could have positive effects on mitigating burdensome requirements for gene therapy
0 Comments
Find out solutions to mitigate the impact from clinical supply chain risk and discover how to improve dynamic drug supply forecasting strategies Join this webinar to learn how supply forecasting and interactive response technology can help biotech companies improve supply planning and distribution while reducing cost and risk Register Enrolling study subjects, setting up patient
0 Comments
The first data detailing Russia’s COVID-19 vaccine—nicknamed Sputnik—was published last week (September 4) in The Lancet. Almost immediately, other scientists began to call attention to unlikely patterns in the data, asking for raw numbers to verify the study’s conclusions. Enrico Bucci, a systems biologist and bioethicist at Temple University, published an open letter on his blog
0 Comments